Sep 10, 2008 by Brian LawlerA Pfizer Drug With a Cloudy FutureThe company offers another drug with mixed odds to the FDA.
Sep 5, 2008 by Brian LawlerWhy Pfizer Made an Interesting Blockbuster Bet Pfizer inks a rich deal to get a late-stage-drug candidate.
Sep 4, 2008 by Brian LawlerSitting Tight in SeptemberSome drugmakers await big news from the FDA this month.
Aug 29, 2008 by Brian LawlerWill Biopharma Acquisitions Never Cease?Enough already! Give us poor, weary reporters a moment to rest.
Aug 28, 2008 by Brian LawlerCell Genesys Takes a Body BlowCan it make a comeback after a failed cancer study of its lead drug?
Aug 26, 2008 by Brian LawlerFDA Changes Course for Elan and Biogen IdecThe agency takes a different tact with one of the partnership's top drugs.
Aug 25, 2008 by Brian LawlerBe Careful With Pay-for-Analyst Research If the company pays, is it safe to play?
Aug 25, 2008 by Brian LawlerKing Triples DownThe pharmaceutical makes an all-in bet on an unproven market.
Aug 21, 2008 by Brian LawlerPDL BioPharma's Partnership Makes SenseBristol-Myers assumes some of the risk of developing a drug for bone marrow cancer.
Aug 21, 2008 by Brian LawlerRegeneron's Results Clearing UpThe drugmaker presents new data on a compelling candidate.
Aug 20, 2008 by Brian LawlerTelaprevir Tests Its LuckExpanding the market for its hepatitis C drug could pay off richly for Vertex.
Aug 18, 2008 by Brian LawlerWhen Breaking Up Isn't Hard to DoPDL BioPharma and Enzon look to spin off parts of their business.
Aug 14, 2008 by Brian LawlerGenentech Asks Roche to Pay Up It isn't going to be taken out at $89 a share.
Aug 14, 2008 by Brian LawlerA Potentially Painless PDUFA DateKing Pharmaceuticals and Pain Therapeutics get an appointment with the FDA.
Aug 13, 2008 by Brian LawlerDilution Lurks at AOBThe pharmaceutical's superb numbers disguise its growing share count.
Aug 12, 2008 by Brian LawlerThe FDA Stands Up CardiomeWhat does the approvable letter mean for Cardiome and other drug developers?
Aug 11, 2008 by Brian LawlerNot Bad, Novo NordiskThe drugmaker's performance is better than its numbers suggest.
Aug 8, 2008 by Brian LawlerFlamel Tries to Get It in GearThe biopharma has irons in the fire, but will they ignite a turnaround?
Aug 6, 2008 by Brian LawlerBioMarin's New Drugs Mostly Hit Their TargetsWhen minor changes in guidance cause increased worries.
